Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    STELARA Crohn's
Show Display Options
Rank Status Study
1 Not yet recruiting A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Intervention: Drug: Ustekinumab
2 Completed
Has Results
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Ustekinumab 90 mg;   Drug: Ustekinumab 4.5 mg/kg;   Drug: Placebo SC;   Drug: Placebo IV
3 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Conditions: Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
4 Recruiting Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: JNJ-64304500;   Drug: Placebo;   Drug: Ustekinumab
5 Completed A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Conditions: Crohn's Disease;   Inflammatory Bowel Disease;   IBD;   Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo;   Drug: Group 2 ustekinumab 130 mg
6 Active, not recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Conditions: Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
Interventions: Drug: Placebo SC;   Drug: Placebo IV;   Drug: Ustekinumab 90 mg SC;   Drug: Ustekinumab 130 mg IV
7 Completed
Has Results
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
Condition: Crohn's Disease
Interventions: Drug: Placebo (IP);   Drug: Ustekinumab 1mg/kg (IP);   Drug: Ustekinumab 3 mg/kg (IP);   Drug: Ustekinumab 6 mg/kg (IP);   Drug: Placebo IV - Responder - Placebo SC (MP);   Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP);   Drug: Ustekinumab IV - Responder - Placebo SC (MP);   Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP);   Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP);   Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)

Study has passed its completion date and status has not been verified in more than two years.